tert-Butyl 4-(3-(2,6-dioxopiperidin-3-yl)-4-oxo-3,4-dihydrophthalazin-6-yl)piperazine-1-carboxylate

Catalog No. :
ACVMYY740
CAS No. :
2753651-44-2
Molecular Formula :
C22H27N5O5
Molecular Weight :
441.49

IUPAC Name:tert-butyl 4-(3-(2,6-dioxopiperidin-3-yl)-4-oxo-3,4-dihydrophthalazin-6-yl)piperazine-1-carboxylate

tert-Butyl 4-(3-(2,6-dioxopiperidin-3-yl)-4-oxo-3,4-dihydrophthalazin-6-yl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
10mg95%$325.00Login to see priceInquiryInquiry
25mg95%$624.00Login to see priceInquiryInquiry
50mg95%$961.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(3-(2,6-dioxopiperidin-3-yl)-4-oxo-3,4-dihydrophthalazin-6-yl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(3-(2,6-dioxopiperidin-3-yl)-4-oxo-3,4-dihydrophthalazin-6-yl)piperazine-1-carboxylate
Molecular FormulaC22H27N5O5
Molecular Weight441.49
SMILESO=C(N1CCN(C2=CC3=C(C=NN(C(CC4)C(NC4=O)=O)C3=O)C=C2)CC1)OC(C)(C)C
InChI KeyZOYPBDXGUQMQPM-UHFFFAOYSA-N
Synonym1-Piperazinecarboxylic acid, 4-[3-(2,6-dioxo-3-piperidinyl)-3,4-dihydro-4-oxo-6-phthalazinyl]-, 1,1-dimethylethyl ester;tert-butyl 4-[3-(2,6-dioxopiperidin-3-yl)-4-oxophthalazin-6-yl]piperazine-1-carboxylate - [AC80580]
CAS No.2753651-44-2

Synthetic Route by SureRoute

1. ACVMYY740 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACVMYY740 route product structure diagram
    ACVMYY7402753651-44-2
Inquiry

2. ACVMYY740 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACMXYO163 route compound structure diagram
    ACMXYO16362595-74-8 In Stock
  4. Then
  5. ACVMYY740 route product structure diagram
    ACVMYY7402753651-44-2
Inquiry

Comments (0)